Could an arthritis drug ease Sjögren's symptoms?
NCT ID NCT01782235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether tocilizumab, a drug that blocks inflammation, can help people with primary Sjögren's syndrome—an autoimmune disease causing dry eyes, dry mouth, pain, and fatigue. Researchers gave 110 participants either tocilizumab or a placebo to see if it could reduce disease activity. The goal was to find a new treatment option for this chronic condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tocilizumab (a drug that blocks IL-6, a protein involved in inflammation)
- What this could lead to
- If successful, this could point toward a new treatment option to control disease activity and improve symptoms in people with primary Sjögren's syndrome.
- What could go wrong
- This is a completed Phase 2/3 trial, but results may not show significant benefit over placebo. Tocilizumab also carries risks like infection, and not all patients may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME (PSS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67098, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.